-transparent.png){kind=logo}
Malignant melanoma, once disseminated, is associated with very short survival times and has proven highly resistant to systemic therapy. Although many chemotherapeutic agents can produce small response rates in these patients, the most consistent responses occur with dacarbazine (DTIC). Numerous combination regimens, with and without DTIC, have been tested against disseminated melanoma, with varying and inconsistent outcomes. The most encouraging results have occurred with the combination of DTIC, cisplatin, BCNU and tamoxifen. The use of high-dose chemotherapy with and without autologous bone marrow support and the addition of biologic agents such as inteferon-alpha and interleukin-2 to conventional chemotherapy have also been actively investigated. This paper reviews the various approaches taken against disseminated melanoma employing systemic chemotherapy.
K L Abbott, and
G S Harman
February 1975,
Cancer,
K L Abbott, and
G S Harman
January 1986,
Acta radiologica. Oncology,
K L Abbott, and
G S Harman
August 1977,
Cancer treatment reports,
K L Abbott, and
G S Harman
April 1967,
The Ohio State medical journal,
K L Abbott, and
G S Harman
September 1978,
La Nouvelle presse medicale,
K L Abbott, and
G S Harman
August 1977,
Minnesota medicine,
K L Abbott, and
G S Harman
June 1972,
Cancer,
K L Abbott, and
G S Harman
August 1993,
Melanoma research,
K L Abbott, and
G S Harman
January 1986,
Archiv fur Geschwulstforschung,
